BioProcess Technology Consultants, Inc. Appoints Riske As Senior Consultant, Ley As Consultant And Promotes Adam To Director, Sales And Marketing
WOBURN, MASSACHUSETTS, June 12, 2014— Bioprocess Technology Consultants, Inc. (BPTC), the leading strategic, technical, and regulatory consulting company for the global biopharmaceutical industry, has appointed Frank J. Riske, Ph.D., as a Senior Consultant, Arthur C. Ley, Ph.D., as a Consultant, and promoted Julia Adam to Director of Sales and Marketing.
Dr. Riske joins BPTC after 14 years at Genzyme, a Sanofi company, where he was a Senior Director in the Late Phase Process Development Group responsible for transforming the group into a high functioning team that reduced process time by 20 percent and became recognized for excellence within the company. Before Genzyme, he held positions at Epic Therapeutics, Repligen, and Hoffmann-LaRoche. He has over 25 years of experience building, leading, and managing cross-functional, multi-site, multi-company teams focusing on process development, technology transfer, equipment implementation and validation, and the production of clinical and commercial material. Dr. Riske received his B.S. in Biology from Fairfield University and his Ph.D. in Biochemistry and Microbiology from Rutgers University, and completed a post-doctoral position at Hoffmann-LaRoche.
"We are excited to bring such a talented downstream processing expert to our team. Frank's addition also serves to expand our expertise in the area of process characterization and technology evaluation and implementation across all types of biopharmaceuticals," said Tom Ransohoff, BPTC Vice President. "Frank's expertise in late-stage process development and scale-up will be an invaluable resource to our clients supporting all phases of their product development."
Dr. Ley has a 25-year proven track record in developing manufacturing processes to advance biotherapeutics from concept to market. Prior to joining BPTC, he served as Vice President Process Sciences at Dyax, where he led the growth of the new Process Sciences Department to assure smooth and rapid transfer of new products into both clinical and commercial manufacturing environments. He was a major contributor to Dyax's successful BLA and MAA submissions for its flagship product Kalbitor, providing expertise on drug substance and drug product and effectively responding to regulatory agency questions. He is also an inventor on numerous US and international patents, including the original US patents for phage display technology. Dr. Ley holds a Ph.D. from the University of California, San Diego (UCSD), and completed post-doctoral training at UCSD and The Rockefeller University.
"Art's breadth of experience from discovery through commercialization will assist many of our clients as they navigate the regulatory path," said Dr. Susan Dana Jones, BPTC Vice President. "His successful experience in all aspects of biopharmaceutical product development, including the preparation and submission of BLAs and MAAs will provide expanded knowledge to support the commercialization of our clients' products."
Since joining BPTC in 2011 as Manager, Sales and Marketing, Julia Adam has been responsible for conceptualizing, developing, and implementing the company's sales and marketing initiatives to help the Company realize its full potential as it expands internationally. She headed BPTC's rebranding initiative in 2011 and has continued to grow BPTC's brand and client base, leading the development of several trademarks, multiple web-based interactive tools, and new business opportunities. Before joining BPTC, she was an independent biotechnology business development consultant for both product and technology-based start-up companies, including BPTC. She was previously at Merrimack Pharmaceuticals, where she established the business development, market research, and public relations functions, helping the company raise $50 million in just over four years. She has also held positions in other industries in which she was responsible for bringing innovation into the organizations. She holds a B.A. in biology from the University of Virginia.
"Julie's numerous contributions to BPTC's business development and marketing efforts over the past several years have been instrumental in establishing BPTC's global presence and vital to our expanding services offerings. Based largely on Julie's efforts, the BPTC website and social network sites are widely recognized as a vital resource for timely information on the bioprocessing industry," said Howard L. Levine, Ph.D., President of BPTC. "We are pleased to announce Julie's promotion and look forward to her continuing efforts to grow BPTC's business through expanded sales and marketing activities." added Dr. Levine.
About BioProcess Technology Consultants
Founded in 1994, BPTC is the recognized worldwide leader in biologics Chemistry, Manufacturing, and Controls (CMC) consulting, providing a full range of technical, regulatory, and strategic assistance to pharmaceutical and biotechnology companies in the development and commercialization of biopharmaceutical products. The company works with clients globally to find and apply solutions to the challenges of biopharmaceutical product development from clone to commercial®. BPTC helps develop manufacturing processes and strategies that enhance the overall value of client companies and accelerate the advancement of new products from clone to clinic®. BPTC also helps investors make informed decisions by providing technical and business evaluations of new products and technologies and product discovery, development, and commercialization plans of potential investments and existing portfolio companies. For more information about BPTC, visit http://www.bptc.comand follow the Company on Twitter at bptcGlobal or LinkedIn at http://www.linkedin.com/company/bioprocess-technology-consultants-inc.